Literature DB >> 23478259

Pharmacotherapy: Optimal blockade of the renin-angiotensin-aldosterone system.

Jürg Nussberger1, Jürgen Bohlender.   

Abstract

Inhibition of the renin–angiotensin–aldosterone system (RAAS) is a successful therapy for hypertension, heart failure, and renal insufficiency. Overdosing of RAAS inhibitors is occasionally observed when several agents are used together, and can cause adverse events such as hypotension, hyperkalaemia, and renal failure. We advocate optimal, rather than complete, RAAS blockade.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23478259     DOI： 10.1038/nrcardio.2013.28

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

2.  Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.

Authors:  J Ménard; D J Campbell; M Azizi; M F Gonzales
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

3.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

4.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

5.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

6.  Angiotensinogen-deficient mice with hypotension.

Authors:  K Tanimoto; F Sugiyama; Y Goto; J Ishida; E Takimoto; K Yagami; A Fukamizu; K Murakami
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

7.  Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.

Authors:  Naomi D L Fisher; A H Jan Danser; J Nussberger; William P Dole; Norman K Hollenberg
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

8.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study.

Authors:  Matthew G Whitbeck; Richard J Charnigo; Paul Khairy; Khaled Ziada; Alison L Bailey; Milagros M Zegarra; Jignesh Shah; Gustavo Morales; Tracy Macaulay; Vincent L Sorrell; Charles L Campbell; John Gurley; Paul Anaya; Hafez Nasr; Rong Bai; Luigi Di Biase; David C Booth; Guillaume Jondeau; Andrea Natale; Denis Roy; Susan Smyth; David J Moliterno; Claude S Elayi
Journal:  Eur Heart J       Date:  2012-11-27       Impact factor: 29.983

Review 9.  Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.

Authors:  Harikrishna Makani; Sripal Bangalore; Kavit A Desouza; Arpit Shah; Franz H Messerli
Journal:  BMJ       Date:  2013-01-28
  9 in total
  6 in total

1.  Optimal renin-angiotensin system blockade-wishful thinking?

Authors:  Harikrishna Makani; Sripal Bangalore; Franz H Messerli
Journal:  Nat Rev Cardiol       Date:  2013-07-02       Impact factor: 32.419

2.  Reply: Optimal renin-angiotensin-aldosterone system blockade--wish fulfilled.

Authors:  Jürg Nussberger; Jürgen Bohlender
Journal:  Nat Rev Cardiol       Date:  2013-07-02       Impact factor: 32.419

3.  Heart failure: New data do not SUPPORT triple RAAS blockade.

Authors:  A H Jan Danser; Anton H van den Meiracker
Journal:  Nat Rev Nephrol       Date:  2015-03-24       Impact factor: 28.314

Review 4.  Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.

Authors:  Raquel Esteras; Maria Vanessa Perez-Gomez; Laura Rodriguez-Osorio; Alberto Ortiz; Beatriz Fernandez-Fernandez
Journal:  Ther Adv Drug Saf       Date:  2015-08

5.  Angiotensin peptide synthesis and cyclic nucleotide modulation in sympathetic stellate ganglia.

Authors:  Emma N Bardsley; Oliver C Neely; David J Paterson
Journal:  J Mol Cell Cardiol       Date:  2019-12-10       Impact factor: 5.000

Review 6.  Neurocardiac regulation: from cardiac mechanisms to novel therapeutic approaches.

Authors:  E N Bardsley; D J Paterson
Journal:  J Physiol       Date:  2018-11-12       Impact factor: 5.182
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.